Blau Farmaceutica (BSP:BLAU3) Debt-to-Asset : 0.17 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Blau Farmaceutica Debt-to-Asset?

Blau Farmaceutica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was R$66 Mil. Blau Farmaceutica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was R$484 Mil. Blau Farmaceutica's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was R$3,241 Mil. Blau Farmaceutica's debt to asset for the quarter that ended in Sep. 2024 was 0.17.

Blau Farmaceutica Debt-to-Asset Historical Data

The historical data trend for Blau Farmaceutica's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blau Farmaceutica Debt-to-Asset Chart

Blau Farmaceutica Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.38

0.54

0.16

0.13

0.20

Blau Farmaceutica Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.20	0.20	0.19	0.18	0.17

Competitive Comparison of Blau Farmaceutica's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blau Farmaceutica's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Blau Farmaceutica's Debt-to-Asset falls into.

Blau Farmaceutica Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Blau Farmaceutica's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(75.018	+	533.52)	/	3053.528
	=	0.20

Blau Farmaceutica's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(65.997	+	483.517)	/	3241.494
	=	0.17

Blau Farmaceutica (BSP:BLAU3) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Blau Farmaceutica Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Blau Farmaceutica's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Blau Farmaceutica Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blau Farmaceutica SA (BSP:BLAU3) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rodovia Raposo Tavares, No. 2833, Km 30.5, Barro Branco, Cotia, SP, BRA, 06705-030

Website

https://www.blau.com

Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.

Blau Farmaceutica Headlines

No Headlines